HOLX - Hologic, Inc.
| Previous Close | 49.82 |
| Open | 50.29 |
| Bid | 49.00 x 800 |
| Ask | 51.35 x 1100 |
| Day's Range | 50.01 - 50.79 |
| 52 Week Range | 37.47 - 52.19 |
| Volume | 1,090,128 |
| Avg. Volume | 1,648,665 |
| Market Cap | 13.486B |
| Beta (3Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 |
| Earnings Date | Nov 5, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.02 |
- GuruFocus.com
Hologic Inc (HOLX) Chairman, President and CEO Stephen P Macmillan Sold $9.5 million of Shares
Chairman, President and CEO of Hologic Inc (30-Year Financial, Insider Trades) Stephen P Macmillan (insider trades) sold 194,396 shares of HOLX on 08/05/2019 at an average price of $48.77 a share. Continue reading...
- Zacks
DexCom (DXCM) Hits 52-Week High, Can the Run Continue?
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- TheStreet.com
Hologic Looks Good as Long as the Stock Doesn't Close Below This Key Level
In his second "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with Steve MacMillan, president and CEO of Hologic Inc. , the medical equipment maker with shares up 24% for the year. MacMillan explained that Hologic's 3D mammography and cervical products are designed to detect cancers earlier, so patients get better outcomes and the health care system overall saves money. In the daily bar chart of HOLX, below, we can see that prices have moved up so far this year but not without a number of retracements or corrections along the way.
- MoneyShow
Acute Care and Women's Health- Breakout Buys in Healthcare
Leo Fasciocco specializes in stocks that have broken out of technical bases; the editor of Ticker Tape Digest reviews two recent buys in the healthcare sector. Both have recently broken out to new all-time highs.
- Business Wire
Hologic Acquires Approximately 46% of Shares in SuperSonic Imagine, a French Innovator in Ultrasound Medical Imaging
Hologic, Inc. (HOLX), a global leader in women’s health, and SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specialized in ultrasound medical imaging, jointly announce today that Hologic Hub Ltd, a wholly-owned indirect subsidiary of Hologic, Inc., has acquired approximately 46% of SuperSonic Imagine shares, pursuant to a shares sale agreement entered into today. “We are very pleased to take this important step in the process of acquiring SuperSonic Imagine, and are excited to begin integrating the company’s best-in-class ultrasound technology, products and people with Hologic’s broader resources for the benefit of women’s breast health,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. SuperSonic Imagine’s main shareholders, namely Bpifrance, Andera Partners, Auriga Partners, Mérieux Participations and CDC PME Croissance, holding together 10,841,409 shares, representing approximately 46% of the outstanding share capital of SuperSonic Imagine, sold all of their shares to Hologic at a price of €1.50 per share.
- Business Wire
Hologic to Webcast Presentation at the Canaccord Genuity 39th Annual Growth Conference
Hologic, Inc. announced today that the Company will present at the Canaccord Genuity 39th Annual Growth Conference in New York, NY on Wednesday, August 7 at 10 a.m. Eastern Time.
- Zacks
Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View
Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.
Motley FoolHologic Inc (HOLX) Q3 2019 Earnings Call Transcript
HOLX earnings call for the period ending June 30, 2019.
- Business Wire
Hologic Announces Financial Results for Third Quarter of Fiscal 2019
– Revenue of $852.4 Million Grows 3.4%, 4.7% in Constant Currency –
- Benzinga
A Preview Of Hologic's Q3 Earnings
Hologic (NASDAQ: HOLX ) unveils its next round of earnings this Wednesday, July 31. Get prepared with Benzinga's ultimate preview for Hologic's Q3 earnings. Earnings and Revenue Analysts expect Hologic ...
- Zacks
Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More
Solid growth in emerging markets is expected to be an added positive this earnings season.
- Zacks
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.
- Zacks
GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand
GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.
- Zacks
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View
Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.
- Zacks
Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View
Omnicell (OMCL) aims at product innovation through R&D.
- Zacks
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.
- Zacks
Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates
Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.
- Zacks
Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand
It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.
- Zacks
ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
- Business Wire
Hologic's Cynosure Division Expands Body Contouring Portfolio with TempSure® Firm for Tissue Heating and Cellulite Treatments and SculpSure® Petite Mask for Submental Fat Reduction
Hologic’s (Nasdaq: HOLX) Cynosure division announced today the launch of two new products that expand the Company’s growing portfolio of innovative aesthetic treatments — the TempSure® Firm handpiece and a petite mask for SculpSure® submental treatments. SculpSure submental treatments are now cleared by the U.S. Food and Drug Administration (FDA) for patients with a body mass index (BMI) up to 49 — the highest BMI clearance on the market for submental treatments. The TempSure Firm handpiece is the latest addition to the TempSure platform.
- Zacks
LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
- Zacks
Align Technology (ALGN) Beats on Q2 Earnings, Margins Fall
We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies.
- Zacks
Integra Lifesciences' (IART) Earnings Top Estimates in Q2
We are upbeat about Integra LifeSciences' (IART) year-over-year revenue growth across key business segments.
- Zacks
Baxter (BAX) Beats on Q2 Earnings & Revenues, Ups EPS View
Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.
- Zacks
NextGen (NXGN) Q1 Earnings Lag Estimates, Revenues Down Y/Y
NextGen (NXGN) slashes guidance for fiscal 2020 owing to a dismal Q1.
